From October 24-26, the CPHI Worldwide 2023 will be held in Barcelona, Spain and Henlius will showcase its integrated biopharmaceutical platform and a wide range of innovative research and development accomplishments for conference attendees, along with its wholly-owned subsidiary, Aton Biotech, a biologics CDMO.
For more than 30 years, CPHI Worldwide has been at the heart of global pharmaceutical industry and is the world's largest gathering of the industry's leading companies and investors from around the world, with numerous collaborative events taking place during the conference. Last year's CPHI Frankfurt 2022 featured 1,846 exhibiting companies and attracted more than 40,000 pharma professionals from 167 countries and regions.
Henlius is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius has pro-actively built a diversified and high-quality product pipeline, including over 60 molecules across monoclonal antibody (mAb), bispecific antibody (BsAb), ADC, fusion protein, and small molecule drug conjugate, of which more than 80% are self-developed. Up to date, 5 products have been launched in China, 1 has been approved for marketing in overseas markets, 19 indications are approved worldwide, and 2 marketing applications have been accepted for review in the U.S., and the EU, respectively.
During CPHI Barcelona 2023, the company will be at Booth #1D50 with 5 launched products, including HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®, the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), and its innovative product HANSIZHUANG, the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Apart from the launched products, Henlius has pro-actively built a diversified and high-quality product pipeline with a focus on oncology, autoimmune diseases, and ophthalmic diseases, covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone.
Henlius is determined to offer high-quality, affordable, and innovative biologic medicines for patients worldwide, focuses on game-changing innovations, and aggressively pursues anti-tumour research and international collaboration. We warmly invite you to visit and connect with us at booth #1D50 at the Fira Barcelona Gran Via, Spain.